COVID-19 - APPOINTMENTS AND PROCEDURES

Your health and safety is still our top priority. Appointments are available as video visits, phone calls or in-person visits as needed, with the same safe, world-class care you expect.

Schedule Now

 

Adult Open Studies

Biology

LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION
Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol
Mark E. Reeves, MD, PhD

Brain

SWOG-NRG-BN001
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT02179086
Joseph Kang, MD
Investigator Initiated-AXUMIN
Differentiating glioma recurrence from treatment-induced necrosis using 18F-fluciclovine (anti-18f-facbc) PET and Multiparametric MR Imaging
https://clinicaltrials.gov/ct2/show/NCT03925675
Warren Boling, MD
SWOG-EAF151
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03115333
Muhammad Kamal, MD

Breast

NSABP-B51
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT01872975
Sharon Lum, MD
Investigator Initiated GRASP-CIPN
A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy.
https://clinicaltrials.gov/ct2/show/NCT03272919
Gayathri Nagaraj, MD
SWOG-S1418-BR006
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Cancer
https://clinicaltrials.gov/ct2/show/NCT02954874
Gayathri Nagaraj, MD
SWOG-BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03199885
Gayathri Nagaraj, MD
SWOG-A011202
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT01901094
Sharon Lum, MD

GI

Colon

SWOG-S0820
Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification
https://www.clinicaltrials.gov/ct2/show/NCT03365882
Chung-Tsen Hsueh, MD, PhD

 

SWOG-S1613
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
https://www.clinicaltrials.gov/ct2/show/NCT01349881
Chung-Tsen Hsueh, MD, PhD

Esophagus

Radiation Medicine
A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904
Gary Yang, MD

Liver

Radiation Medicine
Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases
https://clinicaltrials.gov/ct2/show/NCT01697371
Gary Yang, MD
QED-QBGJ398-301
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
https://clinicaltrials.gov/ct2/show/NCT03773302
Chung-Tsen Hsueh, MD, PhD
NeuWave- NEU-2017-04
A Multicenter Observational Registry to Develop Abation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions
https://clinicaltrials.gov/ct2/show/NCT04107766
Roger Tomihama, MD

Pancreas

Investigator Initiated
A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic https://clinicaltrials.gov/ct2/show/NCT03492671
Naveenraj Solomon, MD

GU

Prostate

Radiation Medicine
A prospective comparative study of outcomes with proton and photon radiation in prostate cancer
https://clinicaltrials.gov/ct2/show/NCT00831623
Jerry Slater, MD
Pfizer-C3441021
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03395197
John Wong, MD

Urethra

SWOG-A031501
hase III randomized “Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADva nced urOthelial caRcinoma” (AMBASSADOR) versus observation
https://clinicaltrials.gov/ct2/show/NCT03244384
John Wong, MD

GYN

Multiple

Investigator Initiated-Paclitaxel
Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in gynecologic-oncology patients: A prospective, randomized, open-label study
https://clinicaltrials.gov/ct2/show/NCT03598426
Linda Hong, MD
SWOG-GY019
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
https://clinicaltrials.gov/ct2/show/NCT04095364
JYevgeniya Ioffe, MD

Ovarian

Investigator Initiated HIPEC
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02672098
Mazdak Momeni, MD

Cervical

GOG-0263
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
https://clinicaltrials.gov/ct2/show/NCT01101451
Yevgeniya Ioffe, MD

Uterine

GOG-0238
A Randomized Trial Of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients With Pelvic-Only Recurrence Of Carcinoma Of The Uterine Corpus
https://clinicaltrials.gov/ct2/show/NCT00492778
Linda Hong, MD

Leukemia

SWOG-A041701
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
https://clinicaltrials.gov/ct2/show/CT03701308
Muhammad O. Kamal, MD

Lung

SWOG-LU003
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
https://clinicaltrials.gov/ct2/show/NCT03737994
Hamid Mirshahidi, MD
SWOG-A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
https://clinicaltrials.gov/ct2/show/NCT02194738
Hamid Mirshahidi, MD
SWOG-E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
https://clinicaltrials.gov/ct2/show/NCT02201992
Hamid Mirshahidi, MD
SWOG-LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
http://clinicaltrials.gov/ct2/show/NCT02154490
Hamid Mirshahidi, MD
SWOG-A081105
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT02194738
Hamid Mirshahidi, MD

Lymphoma

SWOG-A051301
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
https://clinicaltrials.gov/ct2/show/NCT02443077
Muhammad O. Kamal, MD
SWOG-S1608
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03269669
Muhammad O. Kamal, MD

Melenoma

SWOG-S1801
A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma (NCT #03698019)
https://clinicaltrials.gov/ct2/show/NCT03698019
Mark E. Reeves, MD, PhD

Multiple

SWOG-EAY131-MATCH
Molecular Analysis for Therapy Choice (MATCH)
https://clinicaltrials.gov/ct2/show/NCT02465060
Gayathri Nagaraj, MD
SWOG-S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
https://clinicaltrials.gov/ct2/show/NCT02834013
John Wong, MD
COG-AGCT1532
A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors
https://clinicaltrials.gov/ct2/show/NCT02582697
John Wong, MD

Registry

Radiation Medicine
Radiation Medicine Patient Registry
https://clinicaltrials.gov/ct2/show/NCT02436941
Jerry Slater, MD
Penn State-Colon Registry
Prospective observational database of patients with colon cancer at risk of peritoneal recurrence
Maheswari Senthil, MD

Soft Tissue Sarcoma

Radiation Medicine
A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall
https://clinicaltrials.gov/ct2/show/NCT01819831
Gary Yang, MD

Transplant

ATARA - ATA129-EBV-302
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
https://clinicaltrials.gov/ct2/show/NCT03394365
Hamid Mirshahidi, MD